Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USD 550 million...

    USD 550 million awarded in lawsuit linking cancer, baby powder

    Written by Ruby Khatun Khatun Published On 2018-07-15T09:45:18+05:30  |  Updated On 15 July 2018 9:45 AM IST
    USD 550 million awarded in lawsuit linking cancer, baby powder

    R St Louis (US): Nearly two dozen women who claimed asbestos in Johnson and Johnson talcum powder caused their ovarian cancer was awarded USD 550 million in damages by a St Louis jury in the first case against the company that focused on asbestos in the powder.


    Punitive damages are still to be decided for the 22 plaintiffs in a case that began June 4 in St Louis Circuit Court.


    Plaintiffs' lawyer Mark Lanier told the jurors during closing arguments on Wednesday that this case was the first where jurors saw documents showing that Johnson & Johnson knew its products contained asbestos and didn't warn consumers, The St. Louis Post-Dispatch reported.


    "Your voice is not just the voice of the community but the voice of the world," Lanier said. "You don't jack with people's lives like this. ... It's just not right."


    Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company was disappointed with yesterday's verdict but would not comment further until the punitive damages are announced.


    The company has been sued by more than 9,000 women who claim its talcum powder contributed to their ovarian cancer. Johnson & Johnson has consistently denied that its products can be linked to cancer.


    Five previous cases have been decided and Johnson & Johnson has appealed those that it lost.


    During closing arguments, Johnson & Johnson lawyer Peter Bicks said the company for years has exceeded industry standards in testing talcum powder for asbestos and cited several scientific studies and conclusions by US government agencies that he said found the company's products didn't contain asbestos and were safe.


    "Yes, this is terrible," Bicks said of the women's cancer. "But just because something terrible happened doesn't mean Johnson & Johnson had anything to do with it." Six of the 22 plaintiffs in the latest trial have died from ovarian cancer. Five plaintiffs were from Missouri, with others from states that include Arizona, New York, North Dakota, California, Georgia, the Carolinas and Texas.


    One of the plaintiffs, Gail Ingham, 73, of O'Fallon, Missouri, told The Post-Dispatch that she was diagnosed with stage-3 ovarian cancer in 1985 and underwent chemotherapy treatments, surgeries and drug treatments for a year before being declared cancer free in the early 1990s.


    Ingham, who used baby powder for decades, said she joined the lawsuit because women who use baby powder "need to know what's in there. They need to know what's going on. Women need to know because they're putting it on their babies."

    asbestosbaby powdercancerCarol GoodrichJohnson and Johnsonlawsuitovarian cancerSt Louis jurytalcum powder
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok